APA (7th ed.) Citation

H, X., L, L., Y, G., A, A., M, M., AW, H., . . . H, C. (2020). Population pharmacokinetic analysis of phase 1 bemarituzumab data to support phase 2 gastroesophageal adenocarcinoma FIGHT trial. Cancer chemotherapy and pharmacology, 86(5), 595. https://doi.org/10.1007/s00280-020-04139-4

Chicago Style (17th ed.) Citation

H, Xiang, Liu L, Gao Y, Ahene A, Macal M, Hsu AW, Dreiling L, and Collins H. "Population Pharmacokinetic Analysis of Phase 1 Bemarituzumab Data to Support Phase 2 Gastroesophageal Adenocarcinoma FIGHT Trial." Cancer Chemotherapy and Pharmacology 86, no. 5 (2020): 595. https://doi.org/10.1007/s00280-020-04139-4.

MLA (9th ed.) Citation

H, Xiang, et al. "Population Pharmacokinetic Analysis of Phase 1 Bemarituzumab Data to Support Phase 2 Gastroesophageal Adenocarcinoma FIGHT Trial." Cancer Chemotherapy and Pharmacology, vol. 86, no. 5, 2020, p. 595, https://doi.org/10.1007/s00280-020-04139-4.